

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EM 273858988 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 9/9/08 Signature: Valerie J. Sarosky (Valerie J. Sarosky)

PATENTS
NNFF-1 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT APPLICATION

Applicants : Lan Kluwe
Application No. : 10/692,537 Confirmation No. : 9877
Filed : October 24, 2003
For : METHOD FOR THE DETERMINATION OF DATA
FOR THE PREPARATION OF THE DIAGNOSIS
OF PHAKOMATOSIS
Group Art Unit : 1637
Examiner : Young J. Kim

September 9, 2008

Mail Stop Amendment
Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97,
applicants, through their attorneys, make of record the
following documents*:

Non-Patent Documents

Carbonara, C., et al., "Apparent Preferential Loss of
Heterozygosity at TSC2 Over TSC1 Chromosomal Region in
Tuberous Sclerosis Hamartomas," Genes, Chromosomes &
Cancer, 15:18-25 (1996).

09/10/2008 CMGUYEN2 00000034 061075 10692537
02 FC:1806 100.00 DA

* Applicants reserve the right to challenge the status of any
of the cited documents as prior art.

Tory, K., et al., "Specific Genetic Change in Tumors Associated With von Hippel-Lindau Disease," J. Natl. Cancer Inst., 81(14):1097-1101 (1989).

Applicant submits herewith copies of non-patent literature in accordance with 37 CFR 1.98(a)(2).

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the course of the examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO/SB/08 as considered and initialed by the Examiner, be returned with the next communication.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 06-1075 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-1075, under Order No. 105195-0001.

Respectfully submitted,



Jane T. Gunnison (Reg. No. 38,479)
Attorney for Applicants
Joanne M. Holland (Reg. No. 61,315)
Agent for Applicants

ROPES & GRAY LLP
Customer No. 1473
1211 Avenue of the Americas
New York, New York 10036
Tel.: (212) 596-9000
Fax.: (212) 596-9090